At Finch, discovery and product design begins with proof-of-concept data in humans. We begin in the clinic rather than the lab, using interventional studies to understand how the microbiome drives health outcomes. By using machine learning to analyze clinical data and derive relevant strains, Finch is able to identify meaningful microbial signatures. Rather than relying on in-vitro screening of a library of isolates or looking only at associations between health and the microbiome, this Human First Discovery platform allows us to target the microbes that actually cause dysbiosis and disease.